Stock Financial Ratios


MYL / Mylan N.V. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price36.50
Volume4,333,500.00
Market Cap ($M)20,185.83
Enterprise Value ($M)31,209.58
Book Value ($M)11,117.60
Book Value / Share21.36
Price / Book1.52
NCAV ($M)29,685.50
NCAV / Share57.03
Price / NCAV0.64
Income Statement (mra) ($M)
Revenue11,076.90
EBITDA701.60
Net Income480.00
Balance Sheet (mrq) ($M)
Cash & Equivalents614.90
Cash / Share1.18
Assets35,818.90
Liabilities22,527.30
Quick Ratio1.01
Current Ratio1.49
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.01
Return on Equity (ROE)0.04
Identifiers and Descriptors
CUSIPN59465909
Central Index Key (CIK)1623613
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
628530907
062853010
0N5946510
N59465109
628530957
N59465959
010235618
00BVFMFG8
001103120
Share Statistics
Common Shares Outstanding (M)536.44
Scoring Models
Piotroski F Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Long Term Debt Per Share26.88
Liabilities And Stock Equity Per Share68.82
Accounts Receivable Per Share6.19
Additional Paid In Capital Per Share16.47
Retained Earnings Per Share10.36
Liabilities Current Per Share9.58
Debt Per Share1.52
Current Portion Of Long Term Debt Per Share1.52
Accumulated Depreciation And Depletion Per Share3.07
Property Plant And Equipment Per Share4.44
Intangibles Per Share29.34
Inventory Per Share4.90
Assets Current Per Share13.96
Deferred Income Tax Liabilities Per Share4.11
Accounts Payable Per Share2.45
Minority Interest Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Non Current Per Share0.82
Treasury Stock Per Share0.13
Liabilities Per Share43.28
Assets Per Share68.82
Inventory Finished Goods Per Share0.00
Property Plant And Equipment Net Per Share4.44
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Property Plant And Equipment Gross Per Share7.51
Equity Per Share25.54
Cash And Equivalents Per Share1.18
Cash Per Share1.18
Assets Other Current Per Share0.75
Goodwill Per Share19.18
Liabilities Other Non Current Per Share2.71

Related News Stories

Applying My Risk Checklist To General Electric And Mylan

13h seekingalpha
Part of my process is to go through a risk checklist.  Stocks that don't pass are put aside.  Debt ratios and 3 models (Piotroski, Altman, Beneish) are used and shown. (20-0)

Why Fitch Sacked Teva

2017-11-20 seekingalpha
Generic Copaxone could cause Copaxone sales to decline by 70% and total EBITDA to fall by 34%. (365-1)

Tracking John Paulson's Paulson & Company Portfolio - Q3 2017 Update

2017-11-18 seekingalpha
Paulson & Company's largest three positions are the SPDR Gold ETF, Shire plc, and Mylan NV. (1155-7)

Theravance Shares Rise on Approval of Glaxo's COPD Therapy

2017-11-17 zacks
Theravance Biopharma, Inc.’s (TBPH - Free Report) shares rose almost 6.5% on Thursday following the approval of GlaxoSmithKline plc’s (GSK - Free Report) chronic obstructive pulmonary disease ("COPD") therapy, Trelegy Ellipta in Europe. Investors cheered the approval as Theravance has an economic interest on the royalties that Glaxo will pay to its partner Innoviva, Inc. (INVA - Free Report) on global sales of Trelegy Ellipta. (36-0)

What We Can Learn From Teva's Q3 Report

2017-11-17 seekingalpha
Teva has to sell some of its businesses to (1) raise cash for debt repayment and (2) comply with FTC and EC regulations. (134-1)

CUSIP: N59465909